Top Markets
#1 Islamic Coin Islamic Coin +151.49%
#2 DOVU DOVU +48.16%
#3 Velvet Velvet +44.46%
#4 Akedo Akedo +40.57%
#5 Black Phoenix Black Phoenix +33.98%
#6 Cross Cross +24.15%
#7 Cap Cap +20.35%
#8 DoubleZero DoubleZero +14.60%
#9 Tutorial Tutorial +11.59%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +9.77%
Coin of the day
Islamic Coin Islamic Coin
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Peringkat dalam Saham #39467
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Harga Saham
$0.11725176
Terakhir disinkronkan: 2025-07-14
Kapitalisasi Pasar
$481.50K
Perubahan (1 hari)
-0.20%
Perubahan (1 tahun)
0.00%
Negara
FR
Perdagangan PHAXIAM Therapeutics S.A. (PHXM)

Kategori

Healthcare
Rasio P/E untuk PHAXIAM Therapeutics S.A. (PHXM)
Rasio P/E per August 2026 TTM: -0.02
Menurut laporan keuangan dan harga saham terbaru dari PHAXIAM Therapeutics S.A., rasio P/E saat ini (TTM) adalah -0.02. Pada akhir 2022, perusahaan memiliki rasio P/E sebesar -49.90.
Riwayat rasio P/E untuk PHAXIAM Therapeutics S.A. dari 2016 hingga 2026
Rasio P/E di akhir setiap tahun
Tahun Rasio P/E Mengubah
2026 (TTM) -0.02 -97.64%
2023 -0.85 -98.30%
2022 -49.90 5,245.05%
2021 -0.93 -47.66%
2020 -1.78 -7.01%
2019 -1.92 -34.61%
2018 -2.93 -53.24%
2017 -6.27 25.89%
2016 -4.98 0.00%
Rasio P/E untuk perusahaan serupa atau pesaing
Perusahaan Rasio P/E Perbedaan Rasio P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -139,643.28%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -155,046.27%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -96,113.43%
BE
Bagaimana cara membaca P/E ratio?

Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.

Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.

Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.